NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis $0.12 -0.01 (-4.00%) As of 10/9/2026 02:27 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About Hepion Pharmaceuticals Stock (NASDAQ:HEPA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hepion Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.12▼$0.1250-Day Range$0.05▼$0.1352-Week Range$0.03▼$0.13Volume17,081 shsAverage Volume26,584 shsMarket Capitalization$1.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases and certain cancers. The company’s research has centered on rencofilstat, also known as CRV431, an orally administered cyclophilin inhibitor designed to address disease pathways involved in liver injury, fibrosis and tumor development. Hepion has investigated rencofilstat in conditions including metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis), chronic hepatitis B and hepatocellular carcinoma. Its development programs have included clinical studies evaluating the compound’s potential to reduce liver fibrosis and support treatment strategies for patients with serious liver-related diseases. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion Pharmaceuticals name in 2019. Hepion’s operations have been based in the United States, with its clinical development programs conducted through research and trial networks. Robert J. Foster, Ph.D., has been associated with the company’s leadership, including serving as chief executive officer during its development-stage operations.AI Generated. May Contain Errors. Read More Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEPA Stock News HeadlinesHepion Pharmaceuticals (HEPA) Expected to Post Earnings on WednesdayOctober 7 at 1:26 AM | americanbankingnews.comHepion Pharmaceuticals Expands Authorized Share Capital for GrowthOctober 2, 2026 | tipranks.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Hepion Pharmaceuticals Announces New Private Placement FinancingAugust 4, 2026 | tipranks.comHepion Shareholders Expand Equity Plan at 2026 MeetingJune 17, 2026 | tipranks.comHepion Pharmaceuticals Announces Private Placement Financing AgreementApril 22, 2026 | tipranks.comHepion Finalizes CEO Separation Agreement Amid Leadership TransitionApril 14, 2026 | tipranks.comHepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaMarch 3, 2026 | globenewswire.comSee More Headlines HEPA Stock Analysis - Frequently Asked Questions How have HEPA shares performed this year? Hepion Pharmaceuticals' stock was trading at $0.06 on January 1st, 2026. Since then, HEPA stock has increased by 100.0% and is now trading at $0.12. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) issued its earnings results on Thursday, August, 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($200.00) by $199.92. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals shares reverse split on the morning of Tuesday, March 18th 2025.The 1-50 reverse split was announced on Friday, March 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings8/13/2026Today10/10/2026Next Earnings (Estimated)10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HEPA CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees20Year Founded2013Profitability EPS (Trailing Twelve Months)($72.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-812.56% Return on Assets-207.31% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.09Miscellaneous Outstanding Shares11,435,000Free Float6,631,000Market Cap$1.37 million OptionableNo Data Beta1.52 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:HEPA) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
